These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Visual disturbance following sclerotherapy for varicose veins, reticular veins and telangiectasias: a systematic literature review. Willenberg T; Smith PC; Shepherd A; Davies AH Phlebology; 2013 Apr; 28(3):123-31. PubMed ID: 23761921 [TBL] [Abstract][Full Text] [Related]
4. Sclerotherapy: a study comparing polidocanol in foam and liquid form. Uncu H Phlebology; 2010 Feb; 25(1):44-9. PubMed ID: 20118346 [TBL] [Abstract][Full Text] [Related]
5. Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Ukritmanoroat T J Med Assoc Thai; 2011 Mar; 94 Suppl 2():S35-40. PubMed ID: 21717876 [TBL] [Abstract][Full Text] [Related]
6. Incidence of side effects in the treatment of telangiectasias by compression sclerotherapy: hypertonic saline vs. polidocanol. Weiss RA; Weiss MA J Dermatol Surg Oncol; 1990 Sep; 16(9):800-4. PubMed ID: 2398199 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of sodium tetradecyl sulfate and polidocanol as sclerosants for leg telangiectasia based on histological evaluation with clinical correlation. Bush R; Bush P Phlebology; 2017 Aug; 32(7):496-500. PubMed ID: 27738241 [TBL] [Abstract][Full Text] [Related]
8. Nd:Yag laser combined with injection sclerotherapy in the treatment of reticular veins and telangiectasias (CLaCS method): A triple-blind randomized clinical trial comparing two sclerosing agents associated with same laser patterns. Fonseca MM; Mocelin FJ; Grill MH; Gianesini S; Miyake K; Argenta R; Pereira AH Phlebology; 2023 Apr; 38(3):165-171. PubMed ID: 36657386 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. Rabe E; Otto J; Schliephake D; Pannier F Eur J Vasc Endovasc Surg; 2008 Feb; 35(2):238-45. PubMed ID: 17988905 [TBL] [Abstract][Full Text] [Related]
10. Subcutaneous injection of liquid and foamed polidocanol: extravasation is not responsible for skin necrosis during reticular and spider vein sclerotherapy. Schuller-Petrović S; Pavlović MD; Neuhold N; Brunner F; Wölkart G J Eur Acad Dermatol Venereol; 2011 Aug; 25(8):983-6. PubMed ID: 21740464 [TBL] [Abstract][Full Text] [Related]
11. The French polidocanol study on long-term side effects: a survey covering 3,357 patient years. Guex JJ; Schliephake DE; Otto J; Mako S; Allaert FA Dermatol Surg; 2010 Jun; 36 Suppl 2():993-1003. PubMed ID: 20590706 [TBL] [Abstract][Full Text] [Related]
12. Sclerosing foam in the treatment of varicose veins and telangiectases: history and analysis of safety and complications. Frullini A; Cavezzi A Dermatol Surg; 2002 Jan; 28(1):11-5. PubMed ID: 11991262 [TBL] [Abstract][Full Text] [Related]
13. A comparative study between cryo-laser cryo-sclerotherapy and sclerotherapy in the treatment of telangiectasia and reticular veins: A randomized controlled trial. Nasser MM; Ghoneim BM; Eldaly W; Elmahdy H J Vasc Surg Venous Lymphat Disord; 2024 Jul; 12(4):101874. PubMed ID: 38522666 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Hamel-Desnos C; Desnos P; Wollmann JC; Ouvry P; Mako S; Allaert FA Dermatol Surg; 2003 Dec; 29(12):1170-5; discussion 1175. PubMed ID: 14725657 [TBL] [Abstract][Full Text] [Related]
15. [Local drugs in treating and decreasing the incidence of adverse reactions after sclerotherapy of telangiectasia]. Bogachev VI; Boldin BV; Turkin PI; Lobanov VN Angiol Sosud Khir; 2019; 25(4):102-107. PubMed ID: 31855206 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of sclerotherapy with polidocanol foam in comparison with fluid sclerosant in the treatment of first-grade haemorrhoidal disease: a randomised, controlled, single-blind, multicentre trial. Moser KH; Mosch C; Walgenbach M; Bussen DG; Kirsch J; Joos AK; Gliem P; Sauerland S Int J Colorectal Dis; 2013 Oct; 28(10):1439-47. PubMed ID: 23775099 [TBL] [Abstract][Full Text] [Related]
18. Novel developments in foam sclerotherapy: Focus on Varithena® (polidocanol endovenous microfoam) in the management of varicose veins. Star P; Connor DE; Parsi K Phlebology; 2018 Apr; 33(3):150-162. PubMed ID: 28166694 [TBL] [Abstract][Full Text] [Related]
19. Polidocanol (aethoxysklerol) for sclerotherapy of superficial venules and telangiectasias. Goldman PM J Dermatol Surg Oncol; 1989 Feb; 15(2):204-9. PubMed ID: 2644330 [TBL] [Abstract][Full Text] [Related]
20. Comparison of the Safety and Efficacy of Foam Sclerotherapy With 1: 2 Polidocanol to Air Ratio Versus 1: 4 Ratio for the Treatment of Reticular Veins of the Lower Extremities. Hoss E; Kollipara R; Boen M; Alhaddad M; Goldman MP Dermatol Surg; 2020 Dec; 46(12):1715-1720. PubMed ID: 32947299 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]